Menu Search
Equities

Devonian Health Group Inc

DVHGF:PKC

Devonian Health Group Inc

Actions
  • Price (USD)0.1104
  • Today's Change0.00 / 0.00%
  • Shares traded750.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 11 2024 14:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company is focused on developing prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases, including but not limited to ulcerative colitis and atopic dermatitis. It is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health conditions related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., is focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

  • Revenue in CAD (TTM)9.75m
  • Net income in CAD-3.17m
  • Incorporated2017
  • Employees6.00
  • Location
    Devonian Health Group Inc360 rue des EntrepreneursMONTMAGNY G5V 4T1CanadaCAN
  • Phone+1 (514) 248-7509
  • Fax+1 (450) 937-6696
  • Websitehttps://groupedevonian.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.